Cancer staging is one of the fundamental activities in oncology and is of pivotal importance to the modern management of cancer patients. It is structured to represent a major prognostic factor in predicting patients’ outcome and lending order to the complex dynamic behaviour of a cancer.¹ To optimally manage any malignant disease, certain factors must be taken into consideration: the site of origin of the disease, its biology, and the extent of the disease at the time of presentation, i.e. the stage of the tumour.² One of the major purposes of cancer staging, agreed upon internationally, is to offer a classification of a cancer’s extent in order to provide a method of conveying one’s clinical experience to others for the comparison of treatment methods without ambiguity. Cancer staging is in continual evolution as diagnostic tools change and more prognostic information becomes available. In keeping with this, gynaecologic cancer staging has evolved as well. The International Federation of Gynecology and Obstetrics (FIGO) staging has a long-standing tradition and has led to easier comparisons of treatment results all over the world. However, recent developments in imaging and developments of surgical techniques such as endoscopy are difficult to implement by FIGO because these modalities are not readily available in less developed countries. The FIGO staging is regularly updated, based on new evidence and insight in tumour biology. The most recent adaptation of endometrium cancer staging was recently published (Table I).³ The rationale for the changes that were implemented is described hereafter. In addition, changes that were proposed by the Gynecologic Cancer Intergroup, though not implemented in the new FIGO staging, are discussed.⁴

1. **Grouping Stage IA and IB**
   Given the comparable outcomes for the old Stage IA and IB that are reported in the FIGO Annual Reports, both were grouped into Stage IA.

2. **Stage II**
   Stage II no longer has a subset A and B. Involvement of the endocervical glandular portion of the cervix is now considered Stage I.

3. **Stage IIIA, peritoneal cytology**
   Positive peritoneal cytology alone should not be enough for classification as Stage IIIA disease. Several reports with multivariate analyses have shown that positive peritoneal cytology is not an independent prognostic factor if endometrial cancer is limited to the uterus,⁷⁻¹⁰ but is merely related to other unfavourable prognostic factors such as poor differentiation, deep myometrial infiltration or serous histology. Hence, patients with positive peritoneal cytology should not be upgraded to Stage IIIA, nor to a higher stage in Stage I disease. In cases of “upstaging” the disease by positive peritoneal cytology alone, overtreatment may occur. In the new classification, positive cytology has to be reported separately without changing the stage.

4. **Stage IIIC, inguinal lymph node involvement**
   There are only case reports on patients with inguinal metastases at the time of diagnosis in literature.¹¹,¹² Such patients may carry a rather good prognosis similar to other patients with retroperitoneal metastases. Thus, besides retroperitoneal node involvement, patients with inguinal node metastases could also be allocated to Stage IIIC disease instead of being classified as Stage IVB. However, given the lack of good evidence, the FIGO committee decided to maintain allocation of inguinal node metastases to Stage IVB.

5. **Stage IIIC, retroperitoneal lymph node involvement**
   It is proposed to add the statement that, although

---

### Table I: Revised FIGO staging for carcinoma of the endometrium³

| Stage | Description |
|-------|-------------|
| Stage I* | Tumour confined to the corpus uteri |
| IA* | No or less than half myometrial invasion |
| IB* | Invasion equal to or more than half of the myometrium |
| Stage II* | Tumour invades cervical stroma, but does not extend beyond the uterus** |
| Stage III* | Local and/or regional spread of the tumour |
| IIIA* | Tumour invades the serosa of the corpus uteri and/or adnexa* |
| IIIB* | Vaginal and/or parametrial involvement* |
| IIIC1* | Metastases to pelvic lymph nodes* |
| IIIC2* | Positive pelvic nodes |
| IIIC3* | Positive para-aortic lymph nodes with or without positive pelvic lymph nodes |
| Stage IV* | Tumour invades bladder and/or bowel mucosa, and/or distant metastases |
| IVA* | Tumour invasion of bladder and/or bowel mucosa |
| IVB* | Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes |

* Either G1, G2, or G3.  
** Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II.  
# Positive cytology has to be reported separately without changing the stage.
lymphadenectomy is not mandatory to stage all patients with endometrial cancer, it is recommended in operable high-risk clinical Stage I patients and in those with adverse histologic subtypes such as serous or clear cell carcinomas. Lymphadenectomy seems to be particularly important in decision-making for adjuvant therapy. Lymph node-negative patients do not benefit from adjuvant radiotherapy, whereas node-positive patients may benefit from chemotherapy. In patients with surgically staged negative nodes, toxicity might be considerably reduced. The increased awareness of para-aortic nodal involvement and its clinical importance results in a separate classification. As a result, Stage IIIC is now categorised as IIIC1 (indicating positive pelvic nodes) and IIIC2 (indicating positive para-aortic nodes with or without positive pelvic nodes). Although the FIGO committee thus validates the importance of para-aortic node involvement, there is no definition of the extent and quality of lymphadenectomy. Complete para-aortic lymphadenectomy refers to the renal vessels rather than the inferior mesenteric artery as the upper border.

6. Subdivision of Stage IVB

The prognosis of patients with peritoneal involvement is distinctly better than those with parenchymal-visceral and/or extra-abdominal metastases. However, the FIGO committee maintained the old classification.

Clinicians need to implement the new FIGO staging in their practice and the reason why is twofold: (1) to allow comparison of patients between centres and (2) to divide patients and their tumours into prognostic groups.

Frédéric Amant, MD, PhD
Department of Gynaecological Oncology, University Hospitals of Leuven, Leuven, Belgium
E-mail: frederic.amant@uz.kuleuven.ac.be

References

1. Benedet JL, Pecorelli S. Why cancer staging? Int J Gynecol Obstet 2006;95(Suppl 1):S3.
2. Gospodarowicz MK, Benedet L, Hutter RV, et al. History and international developments in cancer staging. Cancer Prev Control 1998;2:262–8.
3. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105(2):103-4, 2009. [PMID: 19367689]
4. Petru E, Liick H-J, Gavin S, et al. Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO system. Eur J Obstet Gynecol Reprod Biol 2008;143:69–74.
5. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet 2009;105:109.
6. Mariani A, Dowdy SC, Podratz KC. New surgical staging of endometrial cancer: 20 years later. Int J Gynecol Obstet 2009;105:110–111.
7. Mariani A, Webb M, Keeney G, et al. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 2002;86:38–44.
8. Kasamatsu T, Onda T, Katsamatu N, et al. Prognostic significance of peritoneal cytology in endometrial carcinoma confined to the uterus. Br J Cancer 2003;27:245–50.
9. Slomovitz B, Ramondetta L, Lee C, et al. Heterogeneity of stage IIB endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer 2005;15:510–6.
10. Tebeu P, Popowski Y, Verkoijen H, et al. Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis. Br J Cancer 2004;16:720–4.
11. Scholtz H, Lax S, Petru E, et al. Inguinal lymph node metastasis as the presenting symptom of endometrial cancer: a case report. Anticancer Res 2002;22:2531–2.
12. Ramahi A, Malviya V, Ataya K, et al. Endometrial carcinoma presenting as a large inguinal mass. Int J Gynecol Obstet 1989;28:67–70.
13. Amant F, Moerman Ph, Neven P, et al. Endometrial Cancer. Lancet 2005;266:491–505.
14. Kitchener H, Redman C, Swart A, et al. ASTEC – a study in the treatment of endometrial cancer: a randomised trial of lymphadenectomy in the treatment of endometrial cancer. Gynecol Oncol 2006;101:S21–2.
15. Chan J, Loizzi V, Youssif M, et al. Significance of comprehensive surgical staging in non-invasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003;90:181–5.
16. Podratz K, Mariani A, Webb M. Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol 1998;70:163–4.
17. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008;109:11–8.
18. Tod Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010 Apr 3;375(9721):1165–72.